Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya (2023)

First Author: Sang S

Attributed to: F Ndungu, Pwani University, Determining Cellular Correlates of Immunity to Malaria in an Experimental Human Challenge Model of Exposed Adults funded by MRC

No abstract provided

Type: Journal Article/Review

Parent Publication: Wellcome Open Research